Chairman
Marqeta, Inc. (MQ)Board Member
Marqeta, Inc. (MQ)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Jason Gardner is recorded as Chairman and Board Member at Marqeta, Inc. (MQ). Jason Gardner was last confirmed as CEO at Dianthus Therapeutics, Inc. /DE/ (DNTH) in a filing dated April 11, 2024. Earlier roles on record: CEO and Board Member at Dianthus Therapeutics, Inc. /DE/ (DNTH) until February 7, 2023. Marqeta, Inc. reported in an 8-K filed May 7, 2024 that Jason Gardner resigned as Executive Chairman, effective June 13, 2024. Dianthus Therapeutics, Inc. /DE/ reported in an 8-K filed February 7, 2023 that Jason Gardner resigned as director, effective February 7, 2023. Marqeta, Inc. reported in an 8-K filed January 26, 2023 that Jason Gardner resigned as Chief Executive Officer, effective January 31, 2023. Equibles holds 4 filed executive changes naming Jason Gardner; each is listed under recent activity with its source filing. The proxy statement of Marqeta, Inc. reports total compensation of $600,764 for Jason Gardner in fiscal 2023, including a base salary of $349,872. Disclosed compensation is on record for 6 fiscal years. Jason Gardner has spoken on 6 earnings calls across 1 company, most recently for Marqeta, Inc. on November 9, 2022.
“On May 6, 2024, Jason Gardner informed the Company's Board of Directors (the "Board") and the Company agreed that Mr. Gardner would step down from his position as Executive Chairman, effective June 13, 2024 (or, if later, the date of the Company's 2024 Annual Meeting of Stockholders, the "Transition Date").”
“Dr. Gardner will no longer serve as a director of the Company, effective as of February 7, 2023.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2023-01-31–present
2010-01-01–present
Start not stated–2024-04-11
Last confirmed by a filing; no departure on record
Start not stated–2023-02-07
Start not stated–2023-02-07
Start not stated–2023-01-31
Start not stated–2024-06-13
Recorded roles and call appearances connecting this person to public companies.
Chairman, Board Member
2010-01-01–present
Other people whose current roles at this company are on record from its filings.
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Marqeta, Inc. (MQ) | Executive Chairman | $349,872 | $600,764 |
| 2023 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | D.Phil. Former President and Chief Executive Officer | $57,861 | $667,649 |
| 2022 | Marqeta, Inc. (MQ) | Executive Chairman | $580,000 | $1,180,634 |
| 2022 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | D.Phil. Former President and Chief Executive Officer | $565,000 | $1,654,848 |
| 2021 | Marqeta, Inc. (MQ) | Executive Chairman | $350,000 | $224,387,431 |
| 2021 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | D.Phil. President and Chief Executive Officer | $545,000 | $2,228,102 |
| 2020 | Marqeta, Inc. (MQ) | Executive Chairman, Former Chief Executive Officer | $350,000 | $1,692,518 |
| 2020 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | D.Phil. President and Chief Executive Officer | $530,000 | $3,102,848 |
| 2019 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | D.Phil. President and Chief Executive Officer | $515,000 | $1,651,001 |
| 2018 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | D.Phil. President and Chief Executive Officer | $460,000 | $4,749,458 |
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
